Scott Kasner, MD
Vascular Neurology · Philadelphia, PANPI 1285666412
Payments from drug & device makers
Across 335 payments — averaging $2722.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$375K
- Medtronic$190K
- Genentech, Inc.$105K
- E.r. Squibb & Sons, L.L.C.$73K
- Sunovion Pharmaceuticals Inc.$54K
- AstraZeneca$37K
- plus $78K from 18 others
Across 22 payments — averaging $968.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Artivion, Inc.$14K
- Medtronic$3K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Novo Nordisk AS$2K
- Livanova USA, Inc.$400
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 79 | $375,491 |
| Medtronic(3 entities) | 70 | $189,753 |
| Genentech, Inc. | 27 | $104,692 |
| E.r. Squibb & Sons, L.L.C. | 22 | $73,280 |
| Sunovion Pharmaceuticals Inc. | 6 | $53,830 |
| AstraZeneca | 15 | $36,770 |
| Bayer | 32 | $13,513 |
| Shionogi Inc | 3 | $12,904 |
| AbbVie | 6 | $9,900 |
| Janssen Global Services, LLC | 10 | $7,749 |
| W. L. Gore & Associates, Inc. | 19 | $7,503 |
| Abbott | 14 | $7,474 |
| Astrazeneca UK Limited | 1 | $3,500 |
| Argenx US, Inc. | 1 | $3,450 |
| Portola Pharmaceuticals, LLC | 9 | $3,293 |
| Stryker | 2 | $2,400 |
| Boehringer Ingelheim International GmbH | 6 | $2,042 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,350 |
| Artivion, Inc. | 2 | $1,300 |
| Sumitomo Pharma America, Inc. | 1 | $1,245 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $365 |
| Biogen | 2 | $149 |
| Philips North America LLC | 4 | $130 |
| Eli Lilly | 1 | $50 |
How this compares
$912,132 in reported general payments places this provider in the 95th percentile of 52 vascular neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other vascular neurology in Philadelphia
- Brett CucchiaraPhiladelphia$1.1M
- Steven MessePhiladelphia$313K
- Michael McGarveyPhiladelphia$71K
- Qingyang YuanPhiladelphia$51K
- Donna GeorgePhiladelphia$4K
- Sydni ColePhiladelphia$408
- Aaron RothsteinPhiladelphia$133
- Paul NovelloPhiladelphia$122
- Christopher FavillaPhiladelphia$109
- Kelley HumbertPhiladelphia$85
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.